Market Research Logo

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016’, provides an overview of the Proliferative Vitreoretinopathy (PVR) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)
    • The report reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects
    • The report assesses Proliferative Vitreoretinopathy (PVR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Proliferative Vitreoretinopathy (PVR) Overview
    Therapeutics Development
    Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Overview
    Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis
    Proliferative Vitreoretinopathy (PVR) - Therapeutics under Development by Companies
    Proliferative Vitreoretinopathy (PVR) - Therapeutics under Investigation by Universities/Institutes
    Proliferative Vitreoretinopathy (PVR) - Pipeline Products Glance
    Early Stage Products
    Proliferative Vitreoretinopathy (PVR) - Products under Development by Companies
    Proliferative Vitreoretinopathy (PVR) - Products under Investigation by Universities/Institutes
    Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development
    Novartis AG
    Promedior, Inc.
    RXi Pharmaceuticals Corporation
    Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LD-224 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRM-167 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XOMA-089 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Proliferative Vitreoretinopathy (PVR) - Dormant Projects
    Proliferative Vitreoretinopathy (PVR) - Product Development Milestones
    Featured News & Press Releases
    Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences
    May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform
    May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
    May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H2 2016
    Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Proliferative Vitreoretinopathy (PVR) - Pipeline by Novartis AG, H2 2016
    Proliferative Vitreoretinopathy (PVR) - Pipeline by Promedior, Inc., H2 2016
    Proliferative Vitreoretinopathy (PVR) - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Proliferative Vitreoretinopathy (PVR) - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H2 2016
    Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report